The Quick Answer

Both Synedica Tirzepatide and Synedica Retatrutide are once-weekly injectable treatments that suppress appetite and drive weight loss by mimicking natural gut hormones. But they are not the same drug. The core difference comes down to how many receptors each targets — and that distinction has a direct impact on how much weight you lose and what side effects you experience.

The practical takeaway for most patients: start with tirzepatide, progress to retatrutide if you plateau at higher doses or want the most comprehensive metabolic approach from the outset. Synedica carries both, and the two products link naturally into a progressive protocol. Read on for the full data breakdown.

How Each Drug Works

To compare these two treatments meaningfully, you need to understand what each receptor actually does in the body.

GLP-1: The Appetite Signal

Both drugs activate GLP-1 (Glucagon-Like Peptide-1). This hormone slows gastric emptying, signals satiety to the brain, and stimulates insulin release. It is the same receptor targeted by semaglutide — and the foundation of all modern incretin therapy.

GIP: The Metabolic Amplifier

GIP (Glucose-Dependent Insulinotropic Polypeptide) works synergistically with GLP-1 to enhance insulin secretion and appears to play a role in fat metabolism and energy regulation. Tirzepatide was the first clinically approved drug to combine GLP-1 and GIP activation, and the combination is what allowed it to outperform semaglutide so substantially.

Glucagon: The Fat-Burning Third Signal

This is where retatrutide breaks new ground. Adding glucagon receptor agonism to the GLP-1/GIP combination increases energy expenditure and promotes fat breakdown (lipolysis) — particularly in the liver. In practical terms, retatrutide makes your body burn more fat even when you are not physically active. This is why its Phase 3 weight loss numbers are higher, and why it shows such strong results for liver fat reduction that tirzepatide alone cannot match.

Weight Loss Results Compared

Phase 3 clinical trial data now gives us a clear head-to-head picture of what each drug delivers at its highest approved doses.

TRIUMPH-1 (Retatrutide) — May 2026

The pivotal Phase 3 TRIUMPH-1 trial enrolled 2,339 participants with obesity or overweight and at least one weight-related comorbidity. At 80 weeks, participants on 12 mg retatrutide lost an average of 25.0% of their body weight — with 45.3% achieving ≥30% weight loss, a threshold previously seen only with bariatric surgery. Even the lowest dose (4 mg) delivered 17.6% average weight loss. (Source: Pharmaceutical Journal, 2026)

SURMOUNT-1 (Tirzepatide) — 2022

The Phase 3 SURMOUNT-1 trial established tirzepatide as the most effective dual agonist available. At 72 weeks, participants on the highest dose (15 mg) lost an average of 22.5% of body weight — a landmark result that saw tirzepatide outperform semaglutide by a significant margin. At 10 mg, average loss was 21.4%. (Source: Lilly / NEJM, 2022)

Beyond Weight: Liver Fat and Metabolic Outcomes

For users with metabolic liver disease (MASLD/NAFLD), the glucagon receptor activation in retatrutide delivers an additional advantage. A Phase 2a sub-study published in Nature Medicine showed 86% of participants on retatrutide 12 mg achieving normal liver fat levels (<5%) at 24 weeks, versus 0% on placebo. This is an area where tirzepatide alone cannot match the triple agonist approach. (Source: Nature Medicine, 2024)

Side Effects: Side by Side

Both drugs share the same family of gastrointestinal side effects — this is a class-wide characteristic of GLP-1-based therapies, not a flaw in either drug specifically. The key differences are in frequency at maximum doses and in a retatrutide-specific effect called dysesthesia.

The pattern is consistent across the data: retatrutide carries a moderately higher GI burden at maximum doses, largely driven by the glucagon receptor component. However, both drugs’ side effects are most prominent during dose escalation and typically subside significantly once you reach a stable maintenance dose. This is exactly why the step-wise Synedica dosing protocol exists — slow escalation is not just recommended, it is the mechanism that makes the treatment tolerable.

Dysesthesia — a tingling or skin-sensitivity sensation unique to retatrutide — appeared in approximately 20.9% of participants at the 12 mg dose in TRIUMPH-4. It was generally mild and rarely caused treatment discontinuation. It is thought to be linked to glucagon receptor activation. Users on the Synedica Retatrutide 40 mg pen should be aware this may occur, particularly as they escalate toward 10 mg doses.

Full Feature Comparison Table

Who Should Use Which?

The established clinical guidance — and the approach recommended by Synedica — is: start with semaglutide → progress to tirzepatide → advance to retatrutide if needed. The body builds tolerance progressively with each receptor, which is why the step-up approach maximises results at each stage.

How to Progress from Tirzepatide to Retatrutide

Transitioning between these two protocols requires care. Here is the general framework based on clinical guidance:

• Complete your current tirzepatide protocol — tolerance typically develops at higher doses (10–15 mg) after sustained use. If weight loss has stalled for 8+ weeks at maximum dose, that is a signal the transition may be appropriate.
• Allow adequate washout time — because both drugs act on GLP-1 and GIP receptors, a brief washout period (or a planned transition week) allows the body to reset sensitivity before the new drug is introduced. Discuss this timing with your provider.
• Start retatrutide at the lowest dose — begin at 2.5 mg weekly using the Synedica Retatrutide 40 mg pen, even if you tolerated high tirzepatide doses well. The glucagon receptor component is a new signal for the body and the escalation protocol exists for good reason.
• Follow the standard escalation — 2.5 mg for weeks 1–4, then 5 mg for weeks 5–8, then 7.5–10 mg from week 9 onwards if needed. See our full Synedica Retatrutide dosage guide for the complete protocol.

The Ongoing Head-to-Head Trial

A direct Phase 3 comparison of retatrutide versus tirzepatide is currently underway. TRIUMPH-5 (NCT06662383) is a Phase 3, randomised, double-blind trial evaluating the efficacy and safety of retatrutide compared directly to tirzepatide in adults with obesity. The study began in November 2024 and is expected to run for approximately 89 weeks. (Source: ClinicalTrials.gov)

Results are anticipated in late 2026 or early 2027. This will be the first time both drugs have been compared head-to-head in the same patient population under identical conditions — and it will likely be the most important metabolic medicine data set of the decade. We will update this article as results emerge.

Frequently Asked Questions